TY - JOUR
T1 - A purification platform for antibodies and derived fragments using a de novo designed affinity adsorbent
AU - Matos, Manuel J. B.
AU - Trovão, Filipa
AU - Gonçalves, João
AU - Rothbauer, Ulrich
AU - Freire, Mara G.
AU - Barbosa, Arménio M. J. B.
AU - Pina, Ana Sofia
AU - Roque, Ana Cecília Afonso
N1 - info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBPD%2F97585%2F2013/PT#
Fundação para a Ciência e Tecnologia (FCT) -PTDC/BII-BIO/28878/2017;
co-financed by ERDF under the PT2020 Partnership Agreement LISBOA-01-0145-FEDER-028878;
PD/BD/128251/2016 from MIT-PT PhD Bioengineering Systems to MJBM;
SFRH/BPD/112543/2015 to AJMB;
Applied Molecular Biosciences Unit – UCIBIO (UIDP/04378/2020 ; UIDB/04378/2020);
CICECO-Aveiro Institute of Materials (UIDB/50011/2020; UIDP/50011/2020), financed by national funds from FCT.
PY - 2021/6/15
Y1 - 2021/6/15
N2 - Antibody technologies are the most representative success-case in the biopharmaceutical industry. Widely available purification technologies fail in providing a dedicated universal purification platform that can accommodate antibodies structural diversity, namely antibodies from non-human sources, as chicken IgY, and antigen-binding fragments. In this work, we took inspiration from natural and engineered antibody-binding ligands, to rationally design affinity adsorbents able to capture full-length antibodies and fragments. The one-pot Petasis and Ugi combinatorial reactions were sequentially employed to rapidly generate a library of putative solid-phase adsorbents. The best performing adsorbent yielded a single-step recovery, under mild conditions, of human and chicken whole antibodies, antigen-binding fragments and engineered single-domain antibodies from different complex feedstocks. Due to its simple preparation, the lead antibody adsorbent finds broad applicability as a universal purification platform to increase the availability of antibody technologies in research and development.
AB - Antibody technologies are the most representative success-case in the biopharmaceutical industry. Widely available purification technologies fail in providing a dedicated universal purification platform that can accommodate antibodies structural diversity, namely antibodies from non-human sources, as chicken IgY, and antigen-binding fragments. In this work, we took inspiration from natural and engineered antibody-binding ligands, to rationally design affinity adsorbents able to capture full-length antibodies and fragments. The one-pot Petasis and Ugi combinatorial reactions were sequentially employed to rapidly generate a library of putative solid-phase adsorbents. The best performing adsorbent yielded a single-step recovery, under mild conditions, of human and chicken whole antibodies, antigen-binding fragments and engineered single-domain antibodies from different complex feedstocks. Due to its simple preparation, the lead antibody adsorbent finds broad applicability as a universal purification platform to increase the availability of antibody technologies in research and development.
KW - Affinity
KW - Antibody fragments, synthetic ligands
KW - Antibody purification
KW - Capture
UR - http://www.scopus.com/inward/record.url?scp=85101305747&partnerID=8YFLogxK
U2 - 10.1016/j.seppur.2021.118476
DO - 10.1016/j.seppur.2021.118476
M3 - Article
AN - SCOPUS:85101305747
SN - 1383-5866
VL - 265
JO - Separation and Purification Technology
JF - Separation and Purification Technology
M1 - 118476
ER -